Important note: Information in this article was accurate in November 2005. The state of the art may have changed since the publication date.
 |
AIDSWEEKLY Plus; Monday, November 7, 2005
Staff Medical Writers
According to recent research from People's Republic of China, "Scutellarin was purified from the plant Erigeron breuiscapus (Vant.) Hand-Mazz.
"The activity against 3 strains of human immunodeficiency virus (HIV) was determined in vitro in this study. These were laboratory-derived virus (HIV-I-IIIB), drug-resistant virus (HIV-1-74V), and low-passage clinical isolated virus (HIV-1(KM018))."
"From syncytia inhibition study, the EC50 of scutellarin against HIV-1-IIB direct infection in C8166 cells was 26 mcM with a therapeutic index of 36.
"When the mode of infection changed from acute infection to cell-to-cell infection, this compound became even more potent and the EC50 reduced to 15 mcM. This suggested that cell fusion might be affected by this compound," reported G.H. Zhang and colleagues at the Chinese Academy of Science.
"By comparing the inhibitory effects on p24 antigen," continued the authors, "scutellarin was also found to be active against HIV-1(74V) (EC50 253 mcM) and HIV-1(KM018) (EC50 136 mcM) infection with significant difference in potency."
"The mechanism of its action was also explored in this study. At a concentration of 433 mcM," investigators said, "scutellarin inhibited 48% of the cell free recombinant HIV-1 RT activity. It also caused 82% inhibition of HIV-1 particle attachment and 45% inhibition of fusion at the concentrations of 54 mcM."
Scientists concluded that scutellarin "was found to inhibit several strains of HIV-1 replication with different potencies. It appeared to inhibit HIV-1 RT activity, HIV-1 particle attachment and cell fusion. These are essential activities for viral transmission and replication."
Zhang and colleagues published their study in Biochemical and Biophysical Research Communications (The anti-HIV-1 effect of scutellarin. Biochem Biophys Res Commun. 2005 Sep 2;334(3):812-6.
For additional information, contact Y.T. Zheng, Chinese Academy Science, Kunming Institute Zoology, Laboratory Molecular Immunopharmacol, Kunming 650223, Yunnan, People's Republic of China.
Publisher contact information for the journal Biochemical and Biophysical Research Communications is: Academic Press Inc. Elsevier Science, 525 B St., Ste. 1900, San Diego, CA 92101-4495, USA.
Keywords: Yunnan, People's Republic of China, Scutellarin, HIV/AIDS, Plant Extract, Anti-HIV Reverse Transcriptase Activity, HIV Entry Inhibitor.
This article was prepared by AIDS Weekly editors from staff and other reports.
Reference
Zhang GH, Wang Q, Chen JJ, et al., "The anti-HIV-1 effect of scutellarin" Biochem Biophys Res Commun. 2005 Sep 2;334(3):812-6.
PubMED Related articles Search
051107
AW051102
Copyright © 2005 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.